SARS-CoV-2疫苗接种后肝损伤:免疫介导性肝炎特征、皮质类固醇治疗作用及结局
该研究收集18个国家87例SARS-CoV-2疫苗接种后肝损伤病例,中位年龄48岁,63%为女性,接种后中位15天诊断。肝损伤以肝细胞型为主(84%),57%患者表现免疫介导性肝炎特征。46例(53%)接受皮质类固醇治疗,除1例(1.1%)发生肝衰竭行肝移植外,所有患者肝损伤均缓解。
要点
- SARS-CoV-2疫苗接种后肝损伤以肝细胞型为主(84%),57%患者有免疫介导性肝炎特征。
- 皮质类固醇更多用于3-4级肝损伤(88.9% vs 43.5%)及免疫介导性肝炎患者(71.1% vs 38.2%)。
- 除1例(1.1%)发生肝衰竭行肝移植外,所有患者肝损伤均缓解,随访期间无复发。
核心结论
- SARS-CoV-2疫苗接种可能与肝损伤相关。
- 皮质类固醇治疗可能对具有免疫介导特征或严重肝炎的患者有益。
- 结局总体良好,但疫苗相关肝损伤导致1例患者发生暴发性肝衰竭。
研究设计与样本
- 研究收集来自18个国家的病例,共87例患者(63%为女性),就诊时中位年龄48岁(范围18-79岁)。
- 肝损伤类型采用R值评估,并根据免疫介导性肝炎特征(自身抗体阳性及免疫球蛋白G水平升高)及是否接受皮质类固醇治疗对研究人群进行分类。
主要发现
- 肝损伤在疫苗接种后中位15天(范围3-65天)被诊断。
- 51例(59%)归因于辉瑞-BioNTech(BNT162b2)疫苗,20例(23%)归因于牛津-阿斯利康(ChAdOX1 nCoV-19)疫苗,16例(18%)归因于Moderna(mRNA-1273)疫苗。
- 肝损伤以肝细胞型为主(84%),57%的患者表现出免疫介导性肝炎特征。
- 46例(53%)患者接受了皮质类固醇治疗;3-4级肝损伤患者接受皮质类固醇的比例高于1-2级肝损伤患者(88.9% vs 43.5%,p=0.001),有免疫介导性肝炎的患者接受皮质类固醇的比例高于无免疫介导性肝炎的患者(71.1% vs 38.2%,p=0.003)。
- 除1例男性(1.1%)发生肝衰竭并接受肝移植外,所有患者肝损伤均缓解;观察期间12例(26%)患者在生化完全缓解后停用类固醇治疗,随访期间无患者复发。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: A few case reports of autoimmune hepatitis-like liver injury have been reported after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination. We evaluated clinical features, treatment response and outcomes of liver injury following SARS-CoV-2 vaccination in a large case series. APPROACH AND RESULTS: We collected data from cases in 18 countries. The type of liver injury was assessed with the R-value. The study population was categorized according to features of immune-mediated hepatitis (positive autoantibodies and elevated immunoglobulin G levels) and corticosteroid therapy for the liver injury. We identified 87 patients (63%, female), median age 48 (range: 18-79) years at presentation. Liver injury was diagnosed a median 15 (range: 3-65) days after vaccination. Fifty-one cases (59%) were attributed to the Pfizer-BioNTech (BNT162b2) vaccine, 20 (23%) cases to the Oxford-AstraZeneca (ChAdOX1 nCoV-19) vaccine and 16 (18%) cases to the Moderna (mRNA-1273) vaccine. The liver injury was predominantly hepatocellular (84%) and 57% of patients showed features of immune-mediated hepatitis. Corticosteroids were given to 46 (53%) patients, more often for grade 3-4 liver injury than for grade 1-2 liver injury (88.9% vs. 43.5%, p = 0.001) and more often for patients with than without immune-mediated hepatitis (71.1% vs. 38.2%, p = 0.003). All patients showed resolution of liver injury except for one man (1.1%) who developed liver failure and underwent liver transplantation. Steroid therapy was withdrawn during the observation period in 12 (26%) patients after complete biochemical resolution. None had a relapse during follow-up. CONCLUSIONS: SARS-CoV-2 vaccination can be associated with liver injury. Corticosteroid therapy may be beneficial in those with immune-mediated features or severe hepatitis. Outcome was generally favorable, but vaccine-associated liver injury led to fulminant liver failure in one patient.
引用
- Efe C, Kulkarni AV, Terziroli Beretta-Piccoli B, et al. Liver injury after SARS-CoV-2 vaccination: Features of immune-mediated hepatitis, role of corticosteroid therapy and outcome. Hepatology. 2022. PMID: 35567545. doi:10.1002/hep.32572
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。